Spero Therapeutics, Inc. (NASDAQ:SPRO) CFO Sells $16,137.42 in Stock

Spero Therapeutics, Inc. (NASDAQ:SPRO) CFO Esther Rajavelu sold 20,689 shares of the firm’s stock in a transaction on Wednesday, February 5th. The stock was sold at an average price of $0.78, for a total value of $16,137.42. Following the completion of the transaction, the chief financial officer now directly owns 724,720 shares in the company, valued at approximately $565,281.60. This represents a 2.78 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website.

Spero Therapeutics Trading Up 16.4 %

SPRO traded up $0.12 during trading on Wednesday, hitting $0.88. 1,489,743 shares of the company traded hands, compared to its average volume of 292,584. The company has a market cap of $47.81 million, a PE ratio of 12.53 and a beta of 0.61. Spero Therapeutics, Inc. has a 1 year low of $0.74 and a 1 year high of $1.89. The stock’s 50-day simple moving average is $0.99 and its two-hundred day simple moving average is $1.19.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on SPRO shares. HC Wainwright reiterated a “buy” rating and set a $5.00 price objective on shares of Spero Therapeutics in a research note on Thursday, January 30th. Evercore ISI cut shares of Spero Therapeutics from an “outperform” rating to an “in-line” rating and set a $5.00 price objective for the company. in a research note on Friday, December 20th. TD Cowen restated a “hold” rating on shares of Spero Therapeutics in a research note on Monday, November 18th. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Spero Therapeutics in a research note on Friday, November 15th.

About Spero Therapeutics

Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company’s product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease.